The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients

被引:270
作者
Filipsson, Helena
Monson, John P.
Koltowska-Haggstrom, Maria
Mattsson, Anders
Johannsson, Gudmundur
机构
[1] Gothenburg Univ, Sahlgrenska Acad, Dept Endocrinol, SE-41345 Gothenburg, Sweden
[2] Queen Mary Univ London, St Bartholomews Hosp, London EC1A 7BE, England
[3] Pfizer, Endocrine Care, KIGS,KIMS,ACROSTUDY Med Outcomes, SE-19190 Sollentuna, Sweden
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
关键词
D O I
10.1210/jc.2006-0524
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid ( GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS ( Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/ dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
引用
收藏
页码:3954 / 3961
页数:8
相关论文
共 42 条
[11]   Very short term dehydroepiandrosterone treatment in female adrenal failure: impact on carbohydrate, lipid and protein metabolism [J].
Christiansen, JJ ;
Gravholt, CH ;
Fisker, S ;
Moller, N ;
Andersen, M ;
Svenstrup, B ;
Bennett, P ;
Ivarsen, P ;
Christiansen, JS ;
Jorgensen, JOL .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (01) :77-85
[12]   Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women [J].
Dhatariya, K ;
Bigelow, ML ;
Nair, KS .
DIABETES, 2005, 54 (03) :765-769
[13]   Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults [J].
Drake, WM ;
Coyte, D ;
Camacho-Hübner, C ;
Jivanji, NM ;
Kaltsas, G ;
Wood, DF ;
Trainer, PJ ;
Grossman, AB ;
Besser, GM ;
Monson, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (11) :3913-3919
[14]  
DUNNE FP, 1995, CLIN ENDOCRINOL, V43, P623, DOI 10.1111/j.1365-2265.1995.tb02928.x
[15]   DAILY CORTISOL PRODUCTION-RATE IN MAN DETERMINED BY STABLE ISOTOPE-DILUTION MASS-SPECTROMETRY [J].
ESTEBAN, NV ;
LOUGHLIN, T ;
YERGEY, AL ;
ZAWADZKI, JK ;
BOOTH, JD ;
WINTERER, JC ;
LORIAUX, DL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (01) :39-45
[16]   Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH [J].
Finamor, FE ;
Lengyel, AMJ .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (11) :871-875
[17]  
FOSSATI P, 1982, CLIN CHEM, V28, P2077
[18]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[19]   The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults:: evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity [J].
Gelding, SV ;
Taylor, NF ;
Wood, PJ ;
Noonan, K ;
Weaver, JU ;
Wood, DF ;
Monson, JP .
CLINICAL ENDOCRINOLOGY, 1998, 48 (02) :153-162
[20]   An assessment of optimal hydrocortisone replacement therapy [J].
Howlett, TA .
CLINICAL ENDOCRINOLOGY, 1997, 46 (03) :263-268